The disclosure also contemplates the use of one or more of the formulations or compositions, in the manufacture of medicaments for treating, abating, reducing, or ameliorating the symptoms of a disease, dysfunction, or disorder in a mammal, such as a human that has, is suspected of having, or at risk for developing an auris interna disorder
Brain Research, 1641 (Pt B), 207-216
Lipo MICC + B12 is a compounded lipotropic injection containing four metabolic support compounds Methionine, Inositol, Choline, and Carnitine combined with Methylcobalamin (the active form of Vitamin B12)
New growth factor therapies aimed at improving intestinal adaptation in short bowel syndrome